Monitoring by doctors leads to better long-term outcomes with inflammation
Glucagon-like peptide-1 (GLP-1) receptor agonists represent a newer class of antidiabetic medications originally approved for type 2 diabetes management
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) concluded in 2024 that available evidence does not support a causal association between GLP-1 receptor agonists and suicidal thoughts or self-harm, though monitoring continues
Whether youre looking to lose weight, gain muscle, regain energy, recover a slowing libido, or relief for something else, correcting hormonal imbalances could be your secret weapon
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
SREBP1cCRY1 signalling represses hepatic glucose production by promoting FOXO1 degradation during refeeding